NEU neuren pharmaceuticals limited

Nonetheless, Bell Potter has named NEU as one of its top 3 stock...

  1. 6,329 Posts.
    lightbulb Created with Sketch. 22868
    Nonetheless, Bell Potter has named NEU as one of its top 3 stock picks for this month.

    BP notes that Daybue CY24 sales were slightly above consensus and also seems happy with the US sales growth outlook for 2025. Further, BP notes Neuren's “unrivalled balance sheet strength” and that the current share price attributes “effectively zero value” to the NNZ-2591 asset, which has already delivered successful Phase 2 results in three separate indications.

    Daybue CY24 US sales of US$348m was within guidance and slightly above consensus…

    Most pleasingly, even the low end of CY25 guidance reflects HSD growth yoy, providing confidence in Daybue's continued growth outlook in the US excluding any Canadian or EU contributions…

    NEU has unrivalled balance sheet strength to prosecute future NNZ-2591 development yet effectively zero value is currently attributed to this asset, likely due to the Ph3 readout timing. We maintain our BUY recommendation which continues to be driven by a positive outlook on NNZ-2591. Licensing income from Daybue alone supports the current share price.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$17.29
Change
0.660(3.97%)
Mkt cap ! $2.178B
Open High Low Value Volume
$16.80 $17.34 $16.63 $9.078M 529.8K

Buyers (Bids)

No. Vol. Price($)
2 1334 $17.18
 

Sellers (Offers)

Price($) Vol. No.
$17.33 2245 3
View Market Depth
Last trade - 16.10pm 31/07/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.